Organisation paid for research Program year 2025 Source: CMS Open Payments

Excel Clinical Research

Neither a doctor nor a teaching hospital

Research payments

$2,963,456

501 payments

Through program year 2025, Excel Clinical Research is reported as receiving $2,963,456 in research payments, across 501 payments.

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$719,125	234
2024	Research	$873,068	49
2023	Research	$657,220	116
2022	Research	$544,177	49
2021	Research	$44,032	36
2020	Research	$113,323	11
2019	Research	$12,512	6

Breakdown

Who paid Research payments · program years 2019–2025

Bavarian Nordic A/S $1,182,639 173 payments
Amgen Inc. $589,638 18 payments
Boehringer Ingelheim International GmbH $539,330 228 payments
Biogen, Inc. $256,543 1 payment
Pfizer Inc. $126,852 16 payments
AbbVie, Inc. $96,825 11 payments
Braintree Laboratories, Inc. $95,317 7 payments
Boehringer Ingelheim Canada Ltd.Ltee $42,081 33 payments
Exeltis, USA Inc. $21,650 7 payments
Allergan Inc. $12,512 6 payments

Studies the money was for Research payments · program years 2019–2025

A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age $638,541 125 payments
Nct05238025 $544,098 48 payments
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis $508,882 205 payments
A Phase 2 Study of RTA 901 in Patients With Diabetic Peripheral Neuropathic Pain (CYPRESS) (CYPRESS) $256,543 1 payment
OUTPOST Clinical Home Use Study $255,225 4 payments
ASCEND P3 AD Extension $100,472 4 payments
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis $95,317 7 payments
Phase 2A Hepatic Impairment $90,323 8 payments
Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine $72,701 10 payments
A Phase 3, Multicenter, Randomized, Open-label, Performance Study With Self-administered Subcutaneous Rocatinlimab (AMG 451) in Adolescent and Adult Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Outpost) $56,930 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.